Zentalis Pharmaceuticals, Inc.
Zentalis Pharmaceuticals, Inc. (ZNTL): 10 pipeline candidates · 8 upcoming catalysts · ~19 mo cash runway · 11 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
18.8 months
D/E 0.39 · 0% dilution
Lead: Phase 3
10 candidates
8 upcoming, next in ~196d
1 buy · 9 sells (180d)
A transparent, data-derived signal for Zentalis Pharmaceuticals, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$257.7M
Cash
$34.6M
Quarterly Burn
$33.0M
Runway
18.8 mo
Revenue
—
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (10 candidates)
| Drug | Phase |
|---|---|
| azenosertib | Phase 3 |
| azenosertib (ZN-c3) | Phase 3 |
| Cetuximab | Phase 1 |
| chemotherapy | Phase 3 |
| Encorafenib | Phase 1 |
| Gemzar | Phase 2 |
| niraparib | Phase 1 |
| Zentalis | Phase 2 |
| ZN-c3 | Phase 2 |
| ZN-d5 | Phase 1 |
Upcoming Catalysts (8)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
98
Total value held
$75.7M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 4,621,414 | $10.8M |
| two sigma investments, lp | 2,956,526 | $6.9M |
| renaissance technologies llc | 1,938,145 | $4.5M |
| citadel advisors llc | 1,756,283 | $4.1M |
| d. e. shaw & co., inc. | 1,484,098 | $3.5M |
| millennium management llc | 1,289,822 | $3.0M |
| blackrock, inc. | 1,269,837 | $3.0M |
| ishara investments lp | 1,230,000 | $2.9M |
| bank of america corp /de/ | 1,132,294 | $2.6M |
| primecap management co/ca/ | 957,420 | $2.2M |
Showing top 10 of 98 institutional holders of Zentalis Pharmaceuticals, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Zentalis Pharmaceuticals, Inc.'s pipeline?
Zentalis Pharmaceuticals, Inc. (ZNTL) has 10 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Zentalis Pharmaceuticals, Inc.'s lead drug candidate?
Zentalis Pharmaceuticals, Inc.'s most advanced tracked candidate is azenosertib (Phase 3) for Solid Tumor; Osteosarcoma; Uterine Serous Carcinoma.
What is Zentalis Pharmaceuticals, Inc.'s next catalyst?
Zentalis Pharmaceuticals, Inc.'s next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: azenosertib" — expected December 31, 2026.
What is Zentalis Pharmaceuticals, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Zentalis Pharmaceuticals, Inc. has approximately 18.8 months of cash runway.
What is Zentalis Pharmaceuticals, Inc.'s market capitalization?
Zentalis Pharmaceuticals, Inc.'s market capitalization is approximately $257.7M.
Get the full picture on Zentalis Pharmaceuticals, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.